Aktienanalyse zu BioVie Inc (BIVI)BIVIBioVie Inc

BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

BioVie Inc is a good buy right now due to its recent price increase of 10.77% over the last 5 days and a strong RSI of 70.093, indicating upward momentum. The stock is currently priced at $2.16, with a projected trajectory suggesting a potential increase of 211.08%. However, the main risk is its negative earnings per share (EPS) of -0.70 reported in the last quarter, which indicates ongoing losses.